On or around 11/13/2018 (Notice of voluntarily dismissal)
Filing Date: June 04, 2018
Mabvax Therapeutics Holdings ("Mabvax") through its subsidiaries develops human antibody-based products and vaccines to address unmet medical needs for the treatment of diseases such as pancreatic, lung, sarcoma ovarian and breast cancer.
According to the law firm press release, the lawsuit alleges that MabVax and other Defendants made materially false and misleading statements and failed to disclose that: (1) that the Company’s internal controls over financial reporting were materially weak and deficient; (2) that the Company had incorrectly calculated and reported beneficial ownership of MabVax shares, and permitted improper influence or control over MabVax, and/or the Company’s officers and directors by certain shareholders; and, (3) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about MabVax’s business, operations, and prospects, were materially false and misleading at all relevant times.
On September 6, 2018, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. The consolidated litigation shall be captioned "In re Mabvax Therapeutics Securities Litigation." Lead Plaintiff filed a consolidated Complaint on October 10.
This case was voluntarily dismissed on November 13, 2018.
Company & Securities Information
Defendant: Mabvax Therapeutics Holdings
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: MBVX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Liam Hardy, et al. v. Mabvax Therapeutics Holdings, et al.
COURT: S.D. California
DOCKET #: 18-CV-01160
JUDGE: Hon. Cynthia Bashant
DATE FILED: 06/04/2018
CLASS PERIOD START: 03/14/2016
CLASS PERIOD END: 05/18/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Glancy Prongay & Murray LLP 1925 Century Park East, Suite 2100 , Glancy Prongay & Murray LLP, CA 90067 (310) 201-9150 (310) 432-1495 ·